In a world first, Malta-based innovation consultancy CLEANTECH360 is delighted to announce that the unique Attomarker Antibody Immunity Test is now available at Remedies Clinic.
This near-patient, rapid diagnostic test – the first of its kind to provide a measure of
COVID-19 antibody immunity and how long it is likely to last – will help individuals
understand their personal COVID risk and to take more informed health decisions. The
test can also establish antibody immunity thresholds for different variants, helping to
maintain an effective vaccine shield to control infection and reduce the prevalence of
the virus.
For the first time, individuals can know whether they have high antibody levels and can
approach a “normal daily life. More importantly, we can identify poor responders or
those with a rapidly waning vaccine or booster effect, so they can protect themselves,
ideally before falling below the ‘edge of immunity.’ This could become a vital test for the
elderly, more vulnerable and regular travellers.
“I am really pleased that our test is being rolled-out in Malta,” says Professor Andrew
Shaw, CEO and Founder of Attomarker. “Rapid, close to patient diagnosis can identify an
individual’s unique antibody profile and immunity status, giving clinicians the information
they need to optimise protective interventions quickly. Additionally, in new phases of the
pandemic, it can rapidly establish antibody levels that support immunity to new variants,
helping guide both individual approaches and more widespread policies.
Attomarker’s test is the only rapid, quantitative, near-patient Antibody Immunity Test
in the world that can tell you the level and type of antibodies you have developed as a
result of vaccination and, if relevant, from natural infection. It can also predict how long
your personal antibody immunity is likely to last into the future, until you reach what is
termed ‘the edge of immunity.’
Prof Shaw continues: “The recognition of personal response to disease and medicines is
increasingly vital, and it enables people to take greater control over their own health. This
test gives people as much information as possible about their Covid immunity, which will
in turn enable them to make more educated decisions about their health.”
Attomarker’s Antibody Immunity test measures IgG antibodies to Nucleocapsid, Spike,
Spike Omicron, RBD, and provides a CRP result (an important measure of
inflammation). It is hoped that, by maintaining an Antibody Immunity Shield, it will be
possible to stop more people from getting infected in the first place. If we can prevent
more infections, less people should be at risk from the potentially life-altering
consequences of long-Covid.
“I am delighted to team up with Remedies to provide Attomarker to the Maltese market.
This development perfectly reflects Malta as an entrepreneurial hub for innovation and
expansion,” says Teuta Oruci, CEO for Malta-based CLEANTECH360, which provides
strategy and growth consulting for the advancement of green technologies.
This is just the first of a number of important medical products currently in
development by Attomarker. The company is already using its unique technology
platform to research and develop further tests: including biomarkers for liver health,
food allergies and fertility. Provided trials are successful, CLEANTECH360 expects to
announce the availability of these tests in Malta in due course.
